

**INITIAL STATEMENT OF BENEFICIAL OWNERSHIP OF SECURITIES**

OMB APPROVAL	
OMB Number:	3235-0104
Estimated average burden hours per response:	0.5

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934 or Section 30(h) of the Investment Company Act of 1940

1. Name and Address of Reporting Person * <u>Bain Capital Life Sciences Investors, LLC</u> <hr/> (Last) (First) (Middle) 200 CLARENDON STREET <hr/> (Street) BOSTON MA 02116 <hr/> (City) (State) (Zip)	2. Date of Event Requiring Statement (Month/Day/Year) 01/14/2020	3. Issuer Name and Ticker or Trading Symbol <u>Aptinyx Inc. [ APTX ]</u>	
		4. Relationship of Reporting Person(s) to Issuer (Check all applicable) Director <input checked="" type="checkbox"/> 10% Owner Officer (give title below) Other (specify below)	5. If Amendment, Date of Original Filed (Month/Day/Year) <hr/> 6. Individual or Joint/Group Filing (Check Applicable Line) Form filed by One Reporting Person <input checked="" type="checkbox"/> Form filed by More than One Reporting Person

**Table I - Non-Derivative Securities Beneficially Owned**

1. Title of Security (Instr. 4)	2. Amount of Securities Beneficially Owned (Instr. 4)	3. Ownership Form: Direct (D) or Indirect (I) (Instr. 5)	4. Nature of Indirect Beneficial Ownership (Instr. 5)
Common Stock	5,558,425	I	See Footnotes <sup>(1)(2)(3)</sup>

**Table II - Derivative Securities Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)**

1. Title of Derivative Security (Instr. 4)	2. Date Exercisable and Expiration Date (Month/Day/Year)		3. Title and Amount of Securities Underlying Derivative Security (Instr. 4)		4. Conversion or Exercise Price of Derivative Security	5. Ownership Form: Direct (D) or Indirect (I) (Instr. 5)	6. Nature of Indirect Beneficial Ownership (Instr. 5)
	Date Exercisable	Expiration Date	Title	Amount or Number of Shares			

1. Name and Address of Reporting Person * <u>Bain Capital Life Sciences Investors, LLC</u> <hr/> (Last) (First) (Middle) 200 CLARENDON STREET <hr/> (Street) BOSTON MA 02116 <hr/> (City) (State) (Zip)		
---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------	--	--

1. Name and Address of Reporting Person * <u>Bain Capital Life Sciences Partners, LP</u> <hr/> (Last) (First) (Middle) 200 CLARENDON STREET <hr/> (Street) BOSTON MA 02116 <hr/> (City) (State) (Zip)		
-------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------	--	--

1. Name and Address of Reporting Person *		
<a href="#">Bain Capital Life Sciences Fund, L.P.</a>		
(Last)	(First)	(Middle)
200 CLARENDON STREET		
(Street)		
BOSTON	MA	02116
(City)	(State)	(Zip)
1. Name and Address of Reporting Person *		
<a href="#">BCIP Life Sciences Associates, LP</a>		
(Last)	(First)	(Middle)
200 CLARENDON STREET		
(Street)		
BOSTON	MA	02116
(City)	(State)	(Zip)
1. Name and Address of Reporting Person *		
<a href="#">Schwartz Jeffrey Lawrence</a>		
(Last)	(First)	(Middle)
200 CLARENDON STREET		
(Street)		
BOSTON	MA	02116
(City)	(State)	(Zip)

**Explanation of Responses:**

- Bain Capital Life Sciences Partners, LP ("BCLSP") is the general partner of Bain Capital Life Sciences Fund, L.P. ("BCLS"). As a result, BCLSP may be deemed to share voting and dispositive power with respect to the securities held by BCLS. BCLS holds 5,042,297 shares of Common Stock. BCLSP disclaims beneficial ownership of such securities except to the extent of its pecuniary interest therein.
- BCIP Life Sciences Associates, LP ("BCIP LS" and, together with BCLS, the "Bain Life Sciences Entities"), whose general partner is Boylston Coinvestors, LLC, holds 516,128 shares of Common Stock.
- Bain Capital Life Sciences Investors, LLC ("BCLSI"), whose managers are Jeffrey Schwartz and Adam Koppel, is the general partner of BCLSP and governs the investment strategy and decision-making process with respect to investments held by BCIP LS. As a result, each of BCLSI, Mr. Schwartz and Dr. Koppel may be deemed to share voting and dispositive power with respect to the securities held by the Bain Life Sciences Entities. BCLSI, Mr. Schwartz and Dr. Koppel each disclaim beneficial ownership of such securities except to the extent of their pecuniary interest therein.

**Remarks:**

[BAIN CAPITAL LIFE SCIENCES INVESTORS, LLC. By: /s/ Adam Koppel. 01/16/2020](#)  
[Name: Adam Koppel, Title: Managing Director](#)

[BAIN CAPITAL LIFE SCIENCES PARTNERS, LP. By: Bain Capital Life Sciences Investors, LLC, its general partner, By: /s/ Adam Koppel. 01/16/2020](#)  
[Name: Adam Koppel, Title: Managing Director](#)

[BAIN CAPITAL LIFE SCIENCES FUND, L.P., By: Bain Capital Life Sciences Partners, LP, its general partner, By: Bain Capital Life Sciences Investors, LLC, its general partner, By: /s/ Adam Koppel, Name: Adam Koppel, Title: Managing Director](#)  
[01/16/2020](#)

BCIP LIFE SCIENCES  
ASSOCIATES, LP, By:  
Boylston Coinvestors, LLC, its 01/16/2020  
general partner, By: /s/ Adam  
Koppel, Name: Adam Koppel,  
Title: Authorized Signatory  
/s/ Jeffrey Schwartz 01/16/2020  
\*\* Signature of Reporting Person      Date

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

\* If the form is filed by more than one reporting person, see Instruction 5 (b)(v).

\*\* Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.

**Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.**